Table 1.
The top 100 cited articles in urology, 2007 and 2012
| Ranking 2012 (2007) | Article | No. citations (2012) | No. citations (2007) |
|---|---|---|---|
| 1 (1) | Feldman HA, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994151:54–61. | 2088 | 1435 |
| 2 (30) | Abrams P, et al. The standardisation of terminology of lower urinary tract function: Report from the International Standardisation Sub-Committee Continence Society. Neurourol Urodyn 2002;21:167–78. | 2030 | 716 |
| 3 (*) | Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24. | 1792 | |
| 4 (*) | Laumann EO, et al. Sexual dysfunction in the United States - Prevalence and predictors. JAMA 1999;281:537–44. | 1742 | |
| 5 (*) | Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34. | 1723 | |
| 6 (7) | Racusen LC, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713–23. | 1694 | 957 |
| 7 (11) | Rosen RC, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30. | 1688 | 901 |
| 8 (*) | Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12. | 1529 | |
| 9 (4) | Palermo G, et al. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992;340:17–8. | 1525 | 1122 |
| 10 (2) | Stamey TA, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909–16. | 1491 | 1250 |
| 11 (58) | Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34. | 1488 | 516 |
| 12 (8) | Barry MJ, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57. | 1397 | 942 |
| 13 (24) | Pound CR, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7. | 1348 | 774 |
| 14 (45) | Wolfe RA, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725–30. | 1312 | 584 |
| 15 (5) | Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156–61. | 1304 | 1052 |
| 16 (12) | Chan JM, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563–6. | 1303 | 901 |
| 17 (3) | Einhorn LH, et al. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293–8. | 1277 | 1209 |
| 18 (59) | Rayman MP. The importance of selenium to human health. Lancet 2000;356:233–41. | 1268 | 514 |
| 19 (*) | Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20. | 1253 | |
| 20 (6) | Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397–404. | 1238 | 973 |
| 21 (17) | Carlsen E, et al. Evidence for decreasing quality of semen during past 50 years. BMJ 1992;305:609–13. | 1225 | 849 |
| 22 (9) | Gleason DF, et al. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58–64. | 1208 | 924 |
| 23 (10) | Sharpe RM, et al. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993;341:1392–5. | 1193 | 910 |
| 24 (100) | D'Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74. | 1112 | 418 |
| 25 (27) | Partin AW, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445–51. | 1107 | 755 |
| 26 (*) | Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24. | 1093 | |
| 27 (25) | Droller MJ, et al. Impotence. JAMA 1993;270:83–90. | 1086 | 761 |
| 28 (14) | Crawford ED, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–24. | 1022 | 870 |
| 29 (18) | Robson CJ, et al. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297–301. | 1020 | 845 |
| 30 (28) | Berry SJ, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–9. | 997 | 751 |
| 31 (33) | Hariharan S, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605–12. | 994 | 665 |
| 32(13) | Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907–23. | 978 | 877 |
| 33 (15) | Solez K, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411–22. | 978 | 862 |
| 34 (22) | Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225–32. | 956 | 803 |
| 35 (19) | Opelz G, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253–9. | 934 | 839 |
| 36 (20) | Loehrer PJ, et al. Drugs 5 years on: Cisplatin. Ann Intern Med 1984;100:704–13. | 933 | 828 |
| 37 (32) | Bolla M, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300. | 929 | 683 |
| 38 (23) | Mebust WK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243–7. | 920 | 784 |
| 39 (16) | Calne RY, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323–7. | 914 | 850 |
| 40 (26) | Belzer FO, et al. Principles of solid organ preservation by cold storage. Transplantation 1988;45:673–6. | 890 | 759 |
| 41 (21) | Gabrilove JL, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414–22. | 856 | 826 |
| 42 (35) | Oesterling JE, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860–4. | 813 | 658 |
| 43 (36) | Catalona WJ, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283–90. | 811 | 657 |
| 44 (51) | Walsh PC, et al. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492–7. | 809 | 561 |
| 45 (54) | Clayman RV, et al. Laparoscopic nephrectomy: initial case report. J Urol 1991;146:278–82. | 806 | 537 |
| 46 (*) | Gardner SD, et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971;1:1253–7. | 799 | |
| 47 (72) | Motzer RJ, et al. Renal-cell carcinoma. N Engl J Med 1996;335:865–75. | 796 | 472 |
| 48 (*) | Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239–46. | 794 | |
| 49 (37) | Williams SD, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435–40. | 786 | 653 |
| 50 (70) | Epstein JI, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74. | 781 | 475 |
| 51(29) | Starzl TE, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000–4. | 774 | 721 |
| 52 (42) | Partin AW, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110–4. | 758 | 594 |
| 53 (39) | Grinyo JM. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321–5. | 749 | 619 |
| 54 (31) | Sidransky D, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706–9. | 747 | 709 |
| 55 (*) | Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–9. | 746 | |
| 56 (*) | Harisinghani MG, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–9. | 741 | |
| 57 (46) | Carter HB, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215–20. | 738 | 581 |
| 58 (55) | Hodge KK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71–4. | 738 | 524 |
| 59 (*) | Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103–11. | 729 | |
| 60 (38) | Gormley GJ, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–91. | 726 | 629 |
| 61 (57) | Patel R, et al. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735–9. | 719 | 519 |
| 62 (43) | Pirsch JD, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977–83. | 711 | 589 |
| 63 (*) | Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56. | 707 | |
| 64 (34) | Cohen DJ, et al. Cysclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984;101:667–82. | 696 | 663 |
| 65 (47) | Catalona WJ, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948–54. | 695 | 579 |
| 66 (52) | Morales A, et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180–3. | 693 | 557 |
| 67 (*) | Rosen RC, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–26. | 692 | |
| 68 (74) | Messing EM, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781–8. | 691 | 460 |
| 69 (49) | Keown P. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029–37. | 683 | 574 |
| 70 (62) | Childs R, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750–8. | 682 | 503 |
| 71 (*) | Bill-Axelson A, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84. | 678 | |
| 72 (50) | Heney NM, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083–6. | 670 | 562 |
| 73 (61) | Litwin MS, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129–35. | 666 | 504 |
| 74 (48) | Chodak GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242–8. | 658 | 576 |
| 75 (75) | Terasaki PI, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333–6. | 647 | 460 |
| 76 (67) | Taplin ME, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393–8. | 635 | 481 |
| 77 (41) | Cosimi AB, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305:308–14. | 631 | 606 |
| 78 (79) | Auger J, et al. Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med 1995;332:281–5. | 626 | 454 |
| 79 (56) | Rajfer J, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90–4. | 625 | 523 |
| 80 (84) | Carani C, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91–5. | 622 | 445 |
| 81 (*) | Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. Arch Intern Med 1957;100:709–14. | 618 | |
| 82 (44) | Bookstein R, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990;247:712–5. | 612 | 587 |
| 83 (*) | Milsom I, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760–6. | 606 | |
| 84 (*) | Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–24. | 601 | |
| 85 (*) | McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98. | 600 | |
| 86 (95) | Groth CG, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036–42. | 581 | 422 |
| 87 (53) | Cohen AJ, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592–5. | 579 | 551 |
| 88 (*) | Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000;356:194–202. | 579 | |
| 89 (64) | Thomas TM, et al. Prevalence of urinary incontinence. Br Med J 1980;281:1243–5. | 576 | 499 |
| 90 (80) | Dong JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884–6. | 561 | 453 |
| 91 (94) | Walsh PC, et al. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983;4:473–85. | 556 | 422 |
| 92 (63) | Almond PS, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752–6 | 552 | 502 |
| 93 (66) | Cooner WH, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146–52 | 551 | 487 |
| 94 (85) | Esrig D, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–64. | 548 | 442 |
| 95 (89) | Chillón M, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475–80. | 546 | 431 |
| 96 (97) | Vincenti F, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161–5. | 540 | 420 |
| 97 (76) | Smith JR, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371–4. | 536 | 459 |
| 98 (87) | Lapides J, et al. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972;107:458–61. | 533 | 436 |
| 99 (65) | Neal DE, et al. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet 1985;1:366–8 | 529 | 498 |
| 100 (69) | Stamey TA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076–83. | 518 | 479 |
*
New articles, not included in the top 100 in 2007.